Kisspeptin improves local ovarian insulin resistance in PCOS by modulating the PI3K/AKT/GLUT4 signaling pathway
PLOS One · 2026
DOI: 10.1371/journal.pone.0342158 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Na Sun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Reproductive Medicine Center, Weifang People's Hospital, Weifang, Shandong Province, China. Hauptthemen laut MEDLINE: Insulin Resistance, Glucose Transporter Type 4, Polycystic Ovary Syndrome, Signal Transduction. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Weifang Health Commission.
Abstract (Originalsprache)
Background
Insulin resistance (IR) is commonly observed in patients with polycystic ovary syndrome (PCOS), affecting 44% to 70% of these individuals. Kisspeptin is a key regulatory factor in energy balance and reproduction, and it may alleviate PCOS-related symptoms by improving insulin resistance.
Methods
In this study, a PCOS-IR mouse model was established using dehydroepiandrosterone (DHEA) and a high-fat diet. The expression of kisspeptin, PI3K, phosphorylated PI3K (p-PI3K), AKT, phosphorylated AKT (p-AKT), and glucose transporter 4 (GLUT4) was measured by immunofluorescence staining, quantitative PCR, and Western blotting. Flow cytometry was used to evaluate mitochondrial membrane potential (MMP) and reactive oxygen species (ROS) levels.
Results
In granulosa cells from PCOS-IR mice, kisspeptin upregulated GLUT4 expression by activating the PI3K/AKT signaling pathway. In vitro experiments showed that kisspeptin significantly reduced ROS levels, enhanced MMP, and improved mitochondrial function.
Conclusion
Kisspeptin improves insulin resistance through the PI3K/AKT/GLUT4 signaling pathway and exerts its effects in vitro in granulosa cells. by protecting mitochondrial function. This study provides potential biomarkers and therapeutic targets for the treatment of PCOS-IR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Reproductive Medicine Center, Weifang People's Hospital, Weifang, Shandong Province, China.
ORCID-Profile: Huagang Ma
Förderung
- Weifang Health Commission
Zitieren
APA
Sun, N., Sun, P., Sun, L., Sun, P., Qi, D., & Ma, H. (2026). Kisspeptin improves local ovarian insulin resistance in PCOS by modulating the PI3K/AKT/GLUT4 signaling pathway. PLOS One. https://doi.org/10.1371/journal.pone.0342158
Vancouver
Sun N, Sun P, Sun L, Sun P, Qi D, Ma H. Kisspeptin improves local ovarian insulin resistance in PCOS by modulating the PI3K/AKT/GLUT4 signaling pathway. PLOS One. 2026. doi:10.1371/journal.pone.0342158
BibTeX
@article{Sun2026,
author = {Sun, Na and Sun, Pingping and Sun, Lilan and Sun, Ping and Qi, Dandan and Ma, Huagang},
title = {Kisspeptin improves local ovarian insulin resistance in PCOS by modulating the PI3K/AKT/GLUT4 signaling pathway},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0342158}
}
EUVIMED